Neoleukin Therapeutics to effect 1-for-5 reverse stock split on Sept 25 to regain Nasdaq compliance

Neurogene Inc.

Reverse stock split at 1-for-5 ratio effective 12:01 a.m. ET on Sept 25, 2023; ticker NLTX unchanged, new CUSIP 64049K203.
Purpose: regain compliance with Nasdaq minimum bid price requirement of $1.00 per share.
Outstanding shares reduced from ~44,026,429 to ~8,805,285; no fractional shares, cash paid in lieu.
Authorized shares decreased from 100,000,000 to 20,000,000 per Certificate of Amendment filed with Delaware.
Proportionate adjustments to exercise prices and shares underlying equity awards and pre-funded warrants.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Neurogene Inc.: Implemented a one-for-five reverse stock split and decreased authorized common shares from 100,000,000 to 20,000,000 (effective 2023-09-25).

Change: charter amendment
Effective: 2023-09-25

Exact text from the filing

the Company filed a Certificate of Amendment (the “Amendment”) to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to implement a one-for-five reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.000001 per share (the “Common Stock”) to be effective as of 12:01 am Eastern time on September 25, 2023 (the “Effective Time”).

View on SEC.gov

49 governance changes filed in the last 30 days. Browse all governance changes →

Neurogene Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-032817

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.